Moneycontrol PRO
Loans
Loans
HomeAuthorViswanath pilla News

Viswanath Pilla

Senior Assistant Editor

Moneycontrol News

Cipla faces heat due to lower offtake of HIV drugs in tender market

BUSINESS

Cipla faces heat due to lower offtake of HIV drugs in tender market

Cipla’s management in its recent investor call indicated that the global tender business sales could be lower by $100-120m in FY19 led by funding crunch and competition.

Govt appoints Rajasthan bureaucrat Shubhra Singh as NPPA Chairman

BUSINESS

Govt appoints Rajasthan bureaucrat Shubhra Singh as NPPA Chairman

Singh has pro-industry credentials, she was Joint Secretary, Department of Industrial Policy & Promotion (DIPP) under Ministry of Commerce and Industry, Government of India betweeb 2014 and 2015.

Global Fund policies impacting fight against AIDS, tuberculosis and malaria

BUSINESS

Global Fund policies impacting fight against AIDS, tuberculosis and malaria

The Global Fund raises and invests nearly $4 billion a year to support programmes run by local experts in countries and communities most in need

Armed with clinical trial data, Indian stent makers prepare to challenge MNC domination

BUSINESS

Armed with clinical trial data, Indian stent makers prepare to challenge MNC domination

India made cardiac stents which were often dismissed globally including by a section of our own doctors as inferior and not proven for safety and efficacy, are finally breaking that mould.

Medical devices maker Trivitron Healthcare plans IPO in 2 years

BUSINESS

Medical devices maker Trivitron Healthcare plans IPO in 2 years

The company has set a revenue target of Rs 1000 crore in next two years, and plans to commercialise a new born screening solution in US.

Apollo Hospitals to hive off pharmacy business into separate entity

BUSINESS

Apollo Hospitals to hive off pharmacy business into separate entity

The proposed move helps Apollo to become compliant with the the prescribed foreign direct investment (FDI) limits and further grow the pharmacy retail business.

IHH assumes control of Fortis, latter’s board approves Rs 4,000cr preferential allotment

BUSINESS

IHH assumes control of Fortis, latter’s board approves Rs 4,000cr preferential allotment

IHH said the mandatory open offer for acquiring up to 26 percent stake from existing shareholders of Fortis would be completed in due course

Aurobindo Pharma beats Q2 profit estimates, buys inhalation assets from Australian firm

BUSINESS

Aurobindo Pharma beats Q2 profit estimates, buys inhalation assets from Australian firm

The net profit was helped by depreciating rupee against dollar and euro in its key US and Europe markets, that constitute nearly three-fourths of sales.

Decoding Modicare: Is the healthcare scheme sustainable, structurally sound?

BUSINESS

Decoding Modicare: Is the healthcare scheme sustainable, structurally sound?

While advocates of the scheme claim PMJAY has saved 600 million people from becoming impoverished due to medical costs, critics too were equally vocal in highlighting structural problems of the scheme

US pricing pressure shows signs of easing as drug makers prune loss-making portfolios

BUSINESS

US pricing pressure shows signs of easing as drug makers prune loss-making portfolios

To beat the pricing pressure and maintain profit margins, large generic drug makers have responded by slashing their generic pipelines and ANDA filings

Fortis CEO Bhavdeep Singh resigns citing professional, personal reasons

BUSINESS

Fortis CEO Bhavdeep Singh resigns citing professional, personal reasons

The hospital chain said Singh will continue in his current capacity till such time his succession planning is crystallised.

Interview: How Cipla plans to bounce back after a weak Q2

BUSINESS

Interview: How Cipla plans to bounce back after a weak Q2

In an interview with Moneycontrol, Kedar Upadhye, Global Chief Financial Officer of Cipla, talked about the company's strategy going forward.

Cipla warns of multiple headwinds it may face in H2FY19, stock tanks 7%

BUSINESS

Cipla warns of multiple headwinds it may face in H2FY19, stock tanks 7%

Cipla said supply bottlenecks, commodity and crude price inflation, lower tender offtake and US sanctions on Iran, could all put pressure on company’s performance going ahead.

Poor healthcare leaves Scheduled Tribe more vulnerable to diseases

BUSINESS

Poor healthcare leaves Scheduled Tribe more vulnerable to diseases

An expert committee report on tribal health points out glaring gaps in tribal healthcare.

Zydus Wellness says two-thirds of Heinz India transaction will be funded via equity

BUSINESS

Zydus Wellness says two-thirds of Heinz India transaction will be funded via equity

The deal, one of the largest M&A transaction in recent times, offers Zydus access to brands such as Complan, Glucon D, Nycil and Sampriti Ghee, including two manufacturing facilities and a nationwide strong distribution network

J&J starts reimbursement programme for Indian patients with faulty ASR hip implants

BUSINESS

J&J starts reimbursement programme for Indian patients with faulty ASR hip implants

The reimbursement programme called as ASR India Patient Assistance Programme (IPAP) will support patients who have been implanted in India with its ASR hip implant from June 2004 to August 2010 and provide reimbursement, if the revision surgery and the tests have taken place within 15 years from the date of the primary hip replacement surgery.

Kilitch Drugs bets on Africa to grow sales in its comeback bid

BUSINESS

Kilitch Drugs bets on Africa to grow sales in its comeback bid

The company is targeting to double the sales in the current financial year, and is well on the track to achieve it.

L&T sticks to FY19 guidance, expects additional govt orders before 2019 general elections

BUSINESS

L&T sticks to FY19 guidance, expects additional govt orders before 2019 general elections

L&T said growth in order inflow was primarily led by government and public sector undertakings, while the private sector investment continues to remain subdued

Lupin promises better show in H2FY19 on US price stability, new launches

BUSINESS

Lupin promises better show in H2FY19 on US price stability, new launches

The company said it sees the pricing erosion in US settle down at single digit from double digit in the previous quarters.

Centre in no hurry to revise PMJAY package rates, private hospitals will have to wait

BUSINESS

Centre in no hurry to revise PMJAY package rates, private hospitals will have to wait

PMJAY or Ayushman Bharat, popularly known as ModiCare, aims to provide Rs 5 lakh coverage to 10 crore poor families or nearly half a billion people and is considered an important scheme politically for Narendra Modi to showcase to voters as he heads for the general elections next year.

CCI approves IHH Healthcare's Rs 4,000 crore acquisition of Fortis

BUSINESS

CCI approves IHH Healthcare's Rs 4,000 crore acquisition of Fortis

With the CCI approval, IHH will be able to make an open offer for an additional 26 percent stake.

Indian API makers expect rise in order inflows amid price hikes, supply disruption in China

BUSINESS

Indian API makers expect rise in order inflows amid price hikes, supply disruption in China

Moneycontrol reported in August that some drug makers are working towards producing APIs and key starting materials in house, while others have started qualifying Indian sources for procurement.

Dr Reddy's gets 8 USFDA observations for Duvvada injectable site

BUSINESS

Dr Reddy's gets 8 USFDA observations for Duvvada injectable site

The company's Duvvada unit, known as FTO-VII, manufactures cytotoxic and hormonal injectables is under warning since November 2015, blocking any new approvals.

Competition Commission's policy prescriptions to make healthcare transparent, affordable

BUSINESS

Competition Commission's policy prescriptions to make healthcare transparent, affordable

CCI, which has so far received 52 cases pertaining to anti-competitive practices in pharmaceutical and healthcare sector, prescribed some policy and regulatory action to address issues choking competition.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347